Key result
Atenolol produces fewer CNS side effects than propranolol at equivalent antihypertensive doses.
Why the study?
Does atenolol reduce side effects compared to propranolol in hypertensive patients with a history of beta-blocker side effects?
Does atenolol reduce side effects compared to propranolol in hypertensive patients with a history of beta-blocker side effects?
p-value: p=<0.05
The hydrophilic beta-blocker atenolol produces significantly fewer CNS side effects than the lipophilic beta-blocker propranolol at equally effective antihypertensive doses.
May favor atenolol over propranolol to limit CNS effects in beta-blocker-intolerant hypertension; leaves open larger randomized confirmation.
A single-blind study was conducted in 52 hypertensive patients, aged 25 to 68 years, to compare the side effects of an equally effective antihypertensive regimen of propranolol and atenolol. All patients had a history of side effects with beta-blocker therapy. Patients were treated with propranolol 40 to 160 mg bid for 8 weeks, followed by atenolol 50 to 100 mg given once daily for 8 weeks, and then rechallenged with the required dosage of propranolol for 8 weeks. Mean systolic and diastolic blood pressures were controlled during all three treatment phases. Side effects showed a definite trend toward improvement during the atenolol treatment phase. CNS side effects, in particular, showed significantly (P less than .05) reduced severity scores and overall incidence rates during the atenolol treatment phase. In conclusion, this study showed that at equally effective antihypertensive dosages the hydrophilic beta blocker atenolol produced significantly fewer CNS side effects than the lipophilic beta blocker propranolol.
No takes yet. Share an insight, caveat, or question.
Fodor et al. (1987) studied Hypertension (n=52). Atenolol vs. Propranolol was evaluated on CNS side effects severity scores and overall incidence rates (p=<0.05). Atenolol produced significantly fewer CNS side effects than propranolol at equally effective antihypertensive dosages (P<0.05).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: